Kevin D. Email and Phone Number

Data scientist and programmer with over 20 years experience in real-world evidence. Strong background in both leadership and hands-on technical roles. Fluency in R and SAS programming allows seamless delivery of projects in either technology (and/or Python if needed). Good knowledge of statistics and statistical modelling, epidemiology, causal inference (propensity scores, IPTW) and machine learning.Experience of a plethora of EHR and claims data sources: CPRD, IMS Disease Analyzer, IMS Oncology Advantage, IMS Oncology Dynamics, IBM Marketscan, Flatiron, Tempus, Optum Market Clarity, Concert AI, Syapse, MDV (Japan).Excellent written and verbal communication with experience of influencing, advising, presenting, team-leading and cross-functional and cross-cultural project management.Technical skills: SAS (20 years, virtually all modules, complex macros)R (5 years, base R, tidyverse, data.table)Python (5 years, numpy, pandas, scikit-learn, tensorflow, keras)SQL (20 years),PySpark (working knowledge),Git, Linux command line, cloud computing systems (e.g. AWS).Publications:de Silva, K. & Kunz, H. (2023) Prediction of Alzheimer's disease from magnetic resonance imaging using a convolutional neural network. Intelligence-Based Medicine, Volume 7, 100091, ISSN 2666-5212https://www.sciencedirect.com/science/article/pii/S2666521223000054Apple, J. & Shenolikar, R. & de Silva, K. & Sun, P. & Spira, A. (2023)Real-world outcomes among patients with EGFR-mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors versus immunotherapy or chemotherapy in the first-line setting.Cancer Medicine, online versionhttps://onlinelibrary.wiley.com/doi/10.1002/cam4.6052Selected Posters:Shah, A. & Apple, J. & Ryan, D. L. & de Silva, K. & Cai, L. & Shenolikar, R. (2022)Real-world utilization of liquid biopsy for epidermal growth factor receptor (EGFR) testing in patients with metastatic non-small cell lung cancer (mNSCLC).Journal of Clinical Oncology 40:28_suppl, 402-402Nieva, J. & Karia, P.S. & Okhuoya, P. & Berktas, M. & Salomensen, R. & Servidio, L. & Chapaneri, J. & de Silva, K. & Martin, E. & Griesinger, F. (2023)A real-world observational study of long term survival (LTS) and treatment patterns after first-line (1L) Osimertinib in patients with epidermal growth factor receptor (EGFR) mutation-positive advanced small cell lung cancer (NSCLC).ESMO 2023